Abstract
Isolation of circulating tumor cells (CTCs) from blood provides a minimally-invasive alternative for basic understanding, diagnosis, and prognosis of metastatic cancer. The roles and clinical values of CTCs are under intensive investigation, yet most studies are limited by technical challenges in the comprehensive enrichment of intact and viable CTCs with minimal white blood cell (WBC) contamination. Here, we report a novel method based on contrast of cell magnetization in biocompatible ferrofluids (a colloidal magnetic nanoparticle suspension), termed as integrated ferrohydrodynamic cell separation (iFCS), that enriches CTCs in a tumor antigen-independent and cell size variation-inclusive manner, achieves a high throughput (12 mL h -1 ), high recovery rate (99.08% at down to ∼10 cells per mL spike ratio), and low WBC contamination (533 cells for every one milliliter blood processed) and is biocompatible. This method will enable large cohort research to define the clinical and diagnostic value of CTC subtypes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1860-1876 |
| Number of pages | 17 |
| Journal | Lab on a Chip |
| Volume | 19 |
| Issue number | 10 |
| DOIs | |
| State | Published - Jan 1 2019 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Bioengineering
- Biochemistry
- Chemistry(all)
- Biomedical Engineering
Cite this
Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells. / Zhao, Wujun; Liu, Yang; Jenkins, Brittany D.; Cheng, Rui; Harris, Bryana N.; Zhang, Weizhong; Xie, Jin; Murrow, Jonathan R; Hodgson, Jamie; Egan, Mary; Bankey, Ana; Nikolinakos, Petros G.; Ali, Haythem Y.; Meichner, Kristina; Newman, Lisa A.; Davis, Melissa B; Mao, Leidong.
In: Lab on a Chip, Vol. 19, No. 10, 01.01.2019, p. 1860-1876.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Tumor antigen-independent and cell size variation-inclusive enrichment of viable circulating tumor cells
AU - Zhao, Wujun
AU - Liu, Yang
AU - Jenkins, Brittany D.
AU - Cheng, Rui
AU - Harris, Bryana N.
AU - Zhang, Weizhong
AU - Xie, Jin
AU - Murrow, Jonathan R
AU - Hodgson, Jamie
AU - Egan, Mary
AU - Bankey, Ana
AU - Nikolinakos, Petros G.
AU - Ali, Haythem Y.
AU - Meichner, Kristina
AU - Newman, Lisa A.
AU - Davis, Melissa B
AU - Mao, Leidong
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Isolation of circulating tumor cells (CTCs) from blood provides a minimally-invasive alternative for basic understanding, diagnosis, and prognosis of metastatic cancer. The roles and clinical values of CTCs are under intensive investigation, yet most studies are limited by technical challenges in the comprehensive enrichment of intact and viable CTCs with minimal white blood cell (WBC) contamination. Here, we report a novel method based on contrast of cell magnetization in biocompatible ferrofluids (a colloidal magnetic nanoparticle suspension), termed as integrated ferrohydrodynamic cell separation (iFCS), that enriches CTCs in a tumor antigen-independent and cell size variation-inclusive manner, achieves a high throughput (12 mL h -1 ), high recovery rate (99.08% at down to ∼10 cells per mL spike ratio), and low WBC contamination (533 cells for every one milliliter blood processed) and is biocompatible. This method will enable large cohort research to define the clinical and diagnostic value of CTC subtypes.
AB - Isolation of circulating tumor cells (CTCs) from blood provides a minimally-invasive alternative for basic understanding, diagnosis, and prognosis of metastatic cancer. The roles and clinical values of CTCs are under intensive investigation, yet most studies are limited by technical challenges in the comprehensive enrichment of intact and viable CTCs with minimal white blood cell (WBC) contamination. Here, we report a novel method based on contrast of cell magnetization in biocompatible ferrofluids (a colloidal magnetic nanoparticle suspension), termed as integrated ferrohydrodynamic cell separation (iFCS), that enriches CTCs in a tumor antigen-independent and cell size variation-inclusive manner, achieves a high throughput (12 mL h -1 ), high recovery rate (99.08% at down to ∼10 cells per mL spike ratio), and low WBC contamination (533 cells for every one milliliter blood processed) and is biocompatible. This method will enable large cohort research to define the clinical and diagnostic value of CTC subtypes.
UR - http://www.scopus.com/inward/record.url?scp=85065818906&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065818906&partnerID=8YFLogxK
U2 - 10.1039/c9lc00210c
DO - 10.1039/c9lc00210c
M3 - Article
C2 - 31041975
AN - SCOPUS:85065818906
VL - 19
SP - 1860
EP - 1876
JO - Lab on a Chip - Miniaturisation for Chemistry and Biology
JF - Lab on a Chip - Miniaturisation for Chemistry and Biology
SN - 1473-0197
IS - 10
ER -